page_banner

Products

Tetrabenzyl Dapagliflozin CAS: 2001088-28-2

Short Description:

Catalog Number: XD93617
Cas: 2001088-28-2
Molecular Formula: C49H49ClO6
Molecular Weight: 769.38
Availability: In Stock 
Price:  
Prepack:  
Bulk Pack: Request Quote

 


Product Detail

Product Tags

Catalog Number XD93617
Product Name Tetrabenzyl Dapagliflozin
CAS 2001088-28-2
Molecular Formula C49H49ClO6
Molecular Weight 769.38
Storage Details Ambient

Product Specification

Appearance White powder
Assay 99% min

 

Tetrabenzyl Dapagliflozin is a chemical compound derived from Dapagliflozin, which is an oral medication indicated for the treatment of type 2 diabetes mellitus. Tetrabenzyl Dapagliflozin is a derivative of Dapagliflozin and has shown potential in enhancing its therapeutic effects.Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that works by inhibiting the reabsorption of glucose in the kidneys, leading to increased urinary glucose excretion and overall reduction in blood glucose levels. It is primarily used to improve glycemic control in patients with type 2 diabetes.Tetrabenzyl Dapagliflozin, as a derivative of Dapagliflozin, has been developed to potentially enhance the pharmacokinetic properties and efficacy of the original compound. It exhibits similar mechanisms of action, inhibiting SGLT2 in the kidneys, but with some modifications to its molecular structure.One potential advantage of Tetrabenzyl Dapagliflozin over Dapagliflozin is its increased stability and solubility. The addition of benzyl groups in the structure enhances its physical properties, making it more stable and soluble in different environments. This improved solubility can enhance the absorption and bioavailability of the drug in the body.Furthermore, Tetrabenzyl Dapagliflozin may have a longer duration of action compared to Dapagliflozin. The modifications in its structure can potentially slow down its metabolism and elimination, leading to a sustained effect on blood glucose levels. This prolonged action may offer better glycemic control and reduce the frequency of dosing.Tetrabenzyl Dapagliflozin is still in the early stages of research and development, and more studies are needed to fully understand its potential therapeutic benefits. The compound shows promise as a potential improvement over Dapagliflozin, but further investigations are required to assess its efficacy, safety, and clinical applications.It is important to note that the use of Tetrabenzyl Dapagliflozin or any pharmaceutical compound should always be done under the supervision and guidance of a healthcare professional. They can provide the necessary information about its indications, dosing, potential side effects, and interactions with other medications.


  • Previous:
  • Next:

  • Close

    Tetrabenzyl Dapagliflozin CAS: 2001088-28-2